Saying Goodbye To The XOMA Royalty PFDs
Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or CVR, for 75% of net proceeds from certain pending litigation. The transaction is expected to close in Q3 2026 and be immediately accretive to LGND earnings per share.
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript
XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript
XOMA Royalty: Preferreds Still Offer Compelling Income Despite Call Risk
XOMAO is XOMA Royalty Corporation's 8.375% cumulative preferred. I believe the core thesis centers on their dividend durability at this point. In my view, this means that as long as XOMA keeps a healthy balance sheet and its yield remains compelling, then XOMAO looks like a viable dividend play. In that sense, XOMA added 24 assets in 2025. They continue aggregating royalty interests, corporate deals, and contracts.
XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.39 per share a year ago.
XOMA Royalty PFD Update: Going Back To My Original Sell Ratings
XOMA Royalty Corporation preferred stocks offer diversification beyond mREITs and banks, but both XOMAO and XOMAP are now rated Sell. Recent high-cost financing and low tangible common equity raise risk concerns; both preferreds trade above par with limited call risk but high downside if called. XOMAP likely faces a call first, but both issues suffer from illiquidity, negative cash flow, and asset coverage concerns relative to similar-yielding regional bank preferreds.
Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know
The mean of analysts' price targets for XOMA Royalty (XOMA) points to an 86.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
XOMA Royalty (XOMA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.28 per share a year ago.
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates
XOMA Royalty (XOMA) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.86 per share a year ago.
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
XOMA aggregates future biotech royalties and milestone rights for stable, diversified revenue streams. However, I believe its preferred shares (under tickers XOMAO and XOMAP) offer attractive yields with cumulative, perpetual dividends. Since XOMA's diversified portfolio features high-potential, recently FDA-approved assets like Ojemda and Miplyffa, I also think the yields should be relatively secure.
What Makes XOMA Royalty (XOMA) a New Buy Stock
XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
